Copyright © Inderes 2011 - present. All rights reserved.

Novo Nordisk

256.45 DKK

+1.83 %

1,012 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

+1.83 %
+3.80 %
-29.78 %
-21.15 %
-29.53 %
-39.75 %
-55.19 %
+14.87 %
+20,498.39 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.15T DKK
Turnover
1.24B DKK
Revenue
309.06B
EBIT %
41.3 %
P/E
11.12
Dividend yield-%
4.56 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.5
2026

Interim report Q1'26

5.8
2026

Interim report Q2'26

4.11
2026

Interim report Q3'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Novo’s once-a-week insulin shot. One would think there’s a lot of demand for that. It’s much more convenient than daily injections. Not today’s news, but important news concerning Novo. prnewswire.com FDA approves Novo Nordisk's Awiqli®, the first and only once-weekly basal... /PRNewswire...
3/31/2026, 7:53 PM
30
Novo Nordisk News Details Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials1 Treatment with orforglipron 36 mg was...
4/3/2026, 4:04 PM
23
Novo initiated a multi-month subscription model for Wegovy preparations, which allows patients paying for their own medication to receive more stable and even more affordable prices, meaning longer contracts bring greater savings. Novo then expects to gain more deeply committed customers...
3/31/2026, 3:24 PM
by Sijoittaja-alokas
22
Yle Uutiset – 16 Apr 26 ”Emme osaa lopettaa syömistä”, sanoo intialaisnainen – halpa kopiolääke tuo... Intialaisfirmat alkoivat tuottaa lihavuuslääke Ozempicin edullisia kopioita, kun lääkeaineen patentti vanheni Intiassa. Yle selvitti, voiko Suomeen tilata lihavuuslääkkeitä Intiasta...
8 hours ago
by Ummon
16
The FDA has approved Lilly’s new weight-loss pill, Foundayon, which is taken once a day without any dietary restrictions. It will go on sale this April and, of course, it will tighten the competition with Novo. As has been reiterated, a tablet makes it easier to use, although injectable...
4/1/2026, 8:43 PM
by Sijoittaja-alokas
12
Novo receives a buy recommendation from SB1 Close today at 12:06 ∙ MarketWire Analysis of Novo Nordisk’s stock began on Tuesday with a buy recommendation from the financial firm SB1 Markets. This is evident from SB1’s memo, which estimates that Novo’s shares are trading at a 20–25...
yesterday
by Beginner
10
Monthly prices are indeed falling sharply. Is this a bit of a race-to-the-bottom for them?
4/10/2026, 4:28 AM
by Cotr
7
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.